Patients with RAS mutations have significantly shorter overall survival (OS) and progression-free survival, indicating that RAS mutations are an independent prognostic factor in MM [8], and NRAS mutations significantly decrease the sensitivity of myeloma to single-agent BTZ therapy [9]. Here, NRAS is linked to plasma cell myeloma.